Get the Stockscreener App
138.00
0.65%
-0.90
After Hours:
138.00
Natera Inc stock is traded at $138.00, with a volume of 1.73M.
It is down -0.65% in the last 24 hours and down -17.84% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$138.90
Open:
$139.4
24h Volume:
1.73M
Relative Volume:
1.35
Market Cap:
$18.84B
Revenue:
$1.53B
Net Income/Loss:
$-214.69M
P/E Ratio:
-78.41
EPS:
-1.76
Net Cash Flow:
$-43.68M
1W Performance:
-1.87%
1M Performance:
-17.84%
6M Performance:
-17.90%
1Y Performance:
+34.41%
1-Day Range:
$137.90
$141.20
1-Week Range:
$136.91
$143.36
52-Week Range:
$92.14
$183.00
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
138.00 | 18.97B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
484.96 | 180.56B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
202.94 | 147.13B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
566.50 | 45.45B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
119.54 | 34.14B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
197.76 | 33.86B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
NeoGenomics Wants Jury Trial In Natera DNA Test Patent Fight - Law360
Judge trims Natera verdict, keeps ad ban and bulk of damages - Daily Journal
Evercore ISI initiates Natera stock with Outperform rating, $170 price target - Investing.com Australia
Non-Invasive Prenatal Testing Market Forecast and Company - GlobeNewswire
Non-Invasive Prenatal Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Eurofins Scientific, F. Hoffmann-La Roche, Invitae, Illumina, Natera, Centogene, and Qiagen - Yahoo Finance
What is the dividend policy of Natera Inc. stockCapitalize on market trends before they peak - jammulinksnews.com
Genetic testing company opens patient service center in Cumberland County - PennLive.com
What is the risk reward ratio of investing in Natera Inc. stockDiscover stocks with explosive growth potential - jammulinksnews.com
How strong is Natera Inc. company’s balance sheetMaximize your portfolio’s growth with expert tips - jammulinksnews.com
What markets is Natera Inc. expanding into Is ATYR stock a good long term investment optionChart Pattern Recommendation For Smart Trading - jammulinksnews.com
How does Natera Inc. compare to its industry peersHigh-yield portfolio picks - jammulinksnews.com
What makes Natera Inc. stock price move sharplyProven Return Strategy Execution - metal.it
Published on: 2025-07-27 21:21:41 - jammulinksnews.com
When is Natera Inc. stock expected to show significant growthRapid wealth creation - jammulinksnews.com
What are Natera Inc. company’s key revenue driversTremendous return rates - jammulinksnews.com
Natera Maintains Strong Buy Rating from Leerink Partners Amid Insider Selling - AInvest
RBC Capital Maintains a Buy on Natera (NTRA) With a $251 PT - Insider Monkey
10 Best Strong Buy Healthcare Stocks to Buy Now - Insider Monkey
What analysts say about Natera Inc. stockTriple-digit growth rates - PrintWeekIndia
U.S. Minimal Residual Disease Testing Market Trends Analysis Report 2025-2033 | Integration with Personalized Medicines, & Rising Incidence and Prevalence of Hematological Malignancies Fueling Growth - GlobeNewswire Inc.
What institutions are buying Natera Inc. stock nowHigh-yield capital appreciation - jammulinksnews.com
Natera CFO Brophy sold $303k in NTRA stock - Investing.com Australia
Natera CFO Brophy sold $303k in NTRA stock By Investing.com - Investing.com Nigeria
Natera's Prospera™ Heart with DQS: A Game-Changer in Transplant Monitoring - AInvest
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT - Yahoo Finance
Natera(NTRA) Plunges 1.50% Amid Insider Sales - AInvest
Natera's Trading Volume Surges 62.2% to $257 Million, Ranks 440th Despite Stock Price Decline - AInvest
Natera Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
SEC Filings Archive 2025-07-22Historical 10-K, 10-Q, 8-K Forms - Stock Titan
Natera CEO Chapman sells $225,928 in shares By Investing.com - Investing.com India
Natera’s chief legal officer sells $3.4 million in stock - Investing.com Australia
Natera CFO Brophy sold $83,852 in NTRA stock - Investing.com
Natera CEO Chapman sells $225,928 in shares - Investing.com
Natera president Fesko sells $273k in stock By Investing.com - Investing.com South Africa
Natera director Sheena Jonathan sells $12953 in shares - Investing.com Australia
Natera president Fesko sells $273k in stock - Investing.com Australia
Natera Inc: President Moshkevich sells $299k in shares - Investing.com
Natera director Sheena Jonathan sells $12953 in shares By Investing.com - Investing.com UK
What drives Natera Inc. stock priceMarket-beating returns - jammulinksnews.com
Is Natera Inc. a good long term investmentMassive portfolio appreciation - jammulinksnews.com
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):